Show Summary Details
Page of

Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial 

Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial
Chapter:
Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial
Author(s):

Daniel C. Brooks

DOI:
10.1093/med/9780199377527.003.0050
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 September 2019

This chapter provides a summary of a landmark study in vascular neurology. Is rivaroxaban noninferior to warfarin in patients with nonvalvular atrial fibrillation in preventing stroke or systemic embolism? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with nonvalvular atrial fibrillation who were at moderate-to-high stroke risk, rivaroxaban was noninferior to warfarin in preventing ischemic or hemorrhagic stroke or systemic embolism. Rivaroxaban was associated with less intracranial hemorrhage than warfarin, but overall rates of major bleeding were similar. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.